ACCL1931
OPEN TO ACCRUAL
Ph3 Levocarnitine Prophylaxis for AYA in ALL Therapy
EA4151
OPEN TO ACCRUAL
Randomized Phase III AutoHCT+Maintenance Rituximab vs Rituximab Alone in MRDneg patients with MCL
UW19086
OPEN TO ACCRUAL
LTFU Protocol for Subjects Treated with Gene-Modified T Cells
UW20062
OPEN TO ACCRUAL
Metabolic Profiling of Leukemic Cells through Isotope Tracing in Patients with CLL
UW22057
OPEN TO ACCRUAL
Single Arm Ph I/II Study of Tazemetostat with Rituximab and Abbrev Bendamustine in Tx of HTBFL
UW22069
OPEN TO ACCRUAL
PH 2 Study MK-2140 in pts with Aggressive and Indolent B-Cell Malignancies
UW22087
OPEN TO ACCRUAL
Phase II Study of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring CLL